Press Release Archive
Press Releases
September 2019
09.24.2019 Finance Pfizer Declares Fourth-Quarter 2019 Dividend 09.24.2019 Medicines Pfizer Presents New Evidence of IBRANCE® (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019 09.24.2019 Partnerships Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology 09.20.2019 Medicines CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma 09.19.2019 Research Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio 09.17.2019 Partnerships TrialSpark and Pfizer collaborating to improve speed and access to clinical trials 09.17.2019 Vaccines Terry Bradshaw and Pfizer Educate Boomers About the Risks of Pneumococcal Pneumonia and the Importance of Vaccination 09.17.2019 Finance Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call With Analysts 09.12.2019 Partnerships Catalia Health and Pfizer collaborate to better understand patient journeys using artificial intelligence and via robot wellness coach 09.09.2019 Research Vaccines Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants 09.06.2019 Medicines Hospira, Inc., Issues A Voluntary Nationwide Recall for one lot of BACTERIOSTATIC WATER for Injection, USP, due to a Potential Lack of Sterility Assurance 09.01.2019 Research Findings Released from NAXOS, a French Real-World Data Analysis and the Largest Real-World Data Analysis on Oral Anticoagulant Effectiveness and Safety in Europe Among Patients with Non-Valvular Atrial Fibrillation
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.